Fractyl Health (NASDAQ:GUTS) Stock Price Down 1.1%

Fractyl Health, Inc. (NASDAQ:GUTS)’s stock price dropped 1.1% during trading on Thursday . The company traded as low as $6.51 and last traded at $6.57. Approximately 69,309 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 383,212 shares. The stock had previously closed at $6.64.

Analyst Ratings Changes

A number of equities research analysts have issued reports on GUTS shares. Morgan Stanley started coverage on shares of Fractyl Health in a report on Tuesday, February 27th. They issued an “overweight” rating and a $18.00 price target on the stock. Bank of America started coverage on shares of Fractyl Health in a report on Tuesday, February 27th. They issued a “buy” rating and a $26.00 price target on the stock. Finally, Evercore ISI started coverage on shares of Fractyl Health in a report on Wednesday, February 28th. They issued an “outperform” rating on the stock.

Fractyl Health Stock Performance

The firm’s 50 day moving average price is $7.67.

Insider Activity

In related news, Director Ajay Royan bought 333,333 shares of the business’s stock in a transaction dated Tuesday, February 6th. The shares were purchased at an average price of $15.00 per share, with a total value of $4,999,995.00. Following the purchase, the director now owns 1,251,900 shares of the company’s stock, valued at approximately $18,778,500. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.